在人工准备冻融胚胎移植周期中加用口服地屈孕酮进行个体化黄体期支持:是否有益?
该回顾性单中心队列研究纳入694例在激素替代治疗(HRT)周期中行单囊胚移植的患者,根据冻融胚胎移植(FET)当日血清孕酮浓度分组:血清孕酮正常(≥8.8 ng/ml)者继续常规方案,血清孕酮低(<8.8 ng/ml)者从FET次日起加用口服地屈孕酮。两组活产率无显著差异(37.8% vs 38.8%,P=0.84),校正后OR 1.01(95%CI 0.69-1.47,P=0.97)。作者认为加用口服地屈孕酮可能挽救低血清孕酮患者的生殖结局,但缺乏随机对照试验。
要点
- 在HRT-FET周期中,78.8%(547/694)的患者血清孕酮正常,21.2%(147/694)的患者血清孕酮低。
- 血清孕酮低者加用口服地屈孕酮后活产率与孕酮正常者无显著差异(37.8% vs 38.8%,P=0.84)。
- 多因素回归显示活产率与研究中的黄体期支持方案无显著关联(校正OR 1.01,95%CI 0.69-1.47,P=0.97)。
核心结论
- 作者认为,对于移植时血清孕酮低的患者,加用口服地屈孕酮可能挽救HRT-FET周期的生殖结局。
- 作者指出,该领域研究仍因缺乏随机对照试验而受限。
研究设计与样本
- 回顾性单中心队列研究,纳入694例在HRT周期中行单囊胚移植的独特患者。
- 黄体期支持使用阴道微粒化孕酮(MVP,400 mg每日两次)。
- 血清孕酮正常(≥8.8 ng/ml)者继续常规方案;血清孕酮低(<8.8 ng/ml)者从FET次日起加用口服地屈孕酮(10 mg每日三次)。
- 主要结局为活产率(LBR),采用多因素回归模型校正相关混杂因素。
主要发现
- 血清孕酮正常者占78.8%(547/694),低血清孕酮者占21.2%(147/694)。
- 活产率在仅用MVP组为37.8%,在MVP+口服地屈孕酮组为38.8%,两组比较P=0.84。
- 多因素logistic回归显示活产率与研究中的方案无显著关联(校正OR 1.01,95%CI 0.69-1.47,P=0.97)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文指出,该领域研究因缺乏随机对照试验而受限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RESEARCH QUESTION: Does additional supplementation with oral dydrogesterone improve reproductive outcomes in patients with low serum progesterone concentrations on the day of frozen embryo transfer (FET) after artificial (HRT) endometrial preparation? DESIGN: Retrospective, single-centre cohort study including 694 unique patients performing single blastocyst transfer in an HRT cycle. For luteal phase support, intravaginal micronized vaginal progesterone (MVP, 400 mg twice daily) was administered. Serum progesterone concentrations were assessed prior to FET and outco-mes were compared among patients with normal serum progesterone (≥8.8 ng/ml) continuing the routine protocol and patients with low serum progesterone (<8.8 ng/ml) who received additional oral dydrogesterone supplementation (10 mg three times daily) from the day after FET onwards. Primary outcome was live birth rate (LBR), with a multivariate regression model correcting for relevant confounders. RESULTS: Normal serum progesterone concentrations were observed in 547/694 (78.8%) of patients who continued only MVP as planned, whereas low (<8.8 ng/ml) serum progesterone concentrations were detected in 147/694 (21.2%) patients who received additional oral dydrogesterone supplementation on top of MVP from the day after FET onwards. LBR was comparable between both groups: 37.8% for MVP-only versus 38.8% for MVP+OD (P = 0.84). The multivariate logistic regression model indicated that LBR was not significantly associated with the investigated approaches (adjusted odds ratio 1.01, 95% confidence interval 0.69-1.47, P = 0.97). CONCLUSIONS: The current findings suggest that additional oral dydrogesterone supplementation in patients with low serum progesterone concentrations at the moment of transfer could have the potential to rescue reproductive outcomes in HRT-FET cycles. This field of research, however, remains hampered by the absence of randomized controlled trials.
引用
- Mackens S, Pais F, Drakopoulos P, et al. Individualized luteal phase support using additional oral dydrogesterone in artificially prepared frozen embryo transfer cycles: is it beneficial? Reprod Biomed Online. 2023. PMID: 37012101. doi:10.1016/j.rbmo.2023.02.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。